All In Biotech

Drug Trial Radar · NCT01336023

Dual Action of Liraglutide and Insulin Degludec in Type 2 Diabetes: A Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide, Insulin Degludec and Liraglutide in Subjects With Type 2 Diabetes

A 26 Week Randomised, Parallel Three-arm, Open-label, Multi-centre, Multinational Treat-to-target Trial Comparing Fixed Ratio Combination of Insulin Degludec and Liraglutide Versus Insulin Degludec or Liraglutide Alone, in Subjects With Type 2 Diabetes Treated With 1-2 Oral Anti-diabetic Drugs (OADs)With a 26 Week Extension

Last checked: Nov 19, 2026Latest source record: Feb 19, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,663 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,663

Actual

Start

May 23, 2011

Primary completion

May 24, 2012

Study completion Nov 22, 2012

Sponsor

Lead sponsor
Novo Nordisk A/SNovo Nordisk (NVO)
Sponsor type
Industry
First posted
Apr 15, 2011

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This trial is conducted globally. The aim of this trial is to compare the efficacy and safety of insulin degludec/liraglutide (IDegLira) versus insulin degludec (IDeg) and liraglutide (Lira) in subjects with type 2 diabetes. Subjects are to continue their pre-trial treatment with metformin or metformin + pioglitazone throughout the entire trial.

Conditions

  • Diabetes
  • Diabetes Mellitus, Type 2

Interventions

  • insulin degludec/liraglutideDrug

    Insulin degludec/liraglutide treatment will be initiated and titrated (individually adjusted) twice weekly according to the mean self measured plasma glucose (SMPG) (fasting). Insulin degludec/liraglutide is injected subcutaneously (under the skin) once daily.

  • insulin degludecDrug

    Insulin degludec treatment will be initiated with 10 U and titrated (individually adjusted) twice weekly according to the mean SMPG (fasting). Insulin degludec is injected subcutaneously (under the skin) once daily.

  • liraglutideDrug

    Liraglutide will be started with 0.6 mg and subsequent 0.6 mg weekly dose escalation to 1.8 mg. Liraglutide dose of 1.8 mg/day will be continued for the remaining part of the trial. Liraglutide is injected subcutaneously (under the skin) once daily.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Mean Change From Baseline in HbA1c (Glycosylated Haemoglobin) at Week 26.Time frame: Week 0, week 26

Locations

302 sites in 20 countries. Site status is shown where the registry gives one.

  • Novo Nordisk Investigational Site

    Birmingham, Alabama

  • Novo Nordisk Investigational Site

    Anaheim, California

  • Novo Nordisk Investigational Site

    Bermuda Dunes, California

  • Novo Nordisk Investigational Site

    Concord, California

  • Novo Nordisk Investigational Site

    Encino, California

  • Novo Nordisk Investigational Site

    Fair Oaks, California

  • Novo Nordisk Investigational Site

    Fresno, California

  • Novo Nordisk Investigational Site

    Greenbrae, California

  • Novo Nordisk Investigational Site

    La Jolla, California

  • Novo Nordisk Investigational Site

    Long Beach, California

  • Novo Nordisk Investigational Site

    Los Angeles, California

  • Novo Nordisk Investigational Site

    Montclair, California

  • Novo Nordisk Investigational Site

    Monterey, California

  • Novo Nordisk Investigational Site

    Orange, California

  • Novo Nordisk Investigational Site

    Poway, California

  • Novo Nordisk Investigational Site

    San Diego, California

  • Novo Nordisk Investigational Site

    San Diego, California

  • Novo Nordisk Investigational Site

    San Diego, California

  • Novo Nordisk Investigational Site

    San Mateo, California

  • Novo Nordisk Investigational Site

    Santa Barbara, California

  • Novo Nordisk Investigational Site

    Tustin, California

  • Novo Nordisk Investigational Site

    Valencia, California

  • Novo Nordisk Investigational Site

    Walnut Creek, California

  • Novo Nordisk Investigational Site

    Colorado Springs, Colorado

  • Novo Nordisk Investigational Site

    Denver, Colorado

  • Novo Nordisk Investigational Site

    Golden, Colorado

  • Novo Nordisk Investigational Site

    Waterbury, Connecticut

  • Novo Nordisk Investigational Site

    Newark, Delaware

  • Novo Nordisk Investigational Site

    Clearwater, Florida

  • Novo Nordisk Investigational Site

    Delray Beach, Florida

  • Novo Nordisk Investigational Site

    Fort Lauderdale, Florida

  • Novo Nordisk Investigational Site

    Hialeah, Florida

  • Novo Nordisk Investigational Site

    Jacksonville, Florida

  • Novo Nordisk Investigational Site

    Kissimmee, Florida

  • Novo Nordisk Investigational Site

    Melbourne, Florida

  • Novo Nordisk Investigational Site

    Miami, Florida

  • Novo Nordisk Investigational Site

    Miami, Florida

  • Novo Nordisk Investigational Site

    Orlando, Florida

  • Novo Nordisk Investigational Site

    Pembroke Pines, Florida

  • Novo Nordisk Investigational Site

    Tampa, Florida

Showing 40 of 302 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.